Oncolytics reports pelareorep active alongside pan-RAS inhibitor in CRC
Oncolytics Biotech has published preclinical data showing its lead candidate pelareorep retains antitumour activity when co-administered with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, adding early biological rationale for a combination approach in a tumour type where RAS mutations are near-universal.
The NASDAQ-listed company said that during an initial intensive-dosing period, in which pelareorep was given every other day, all three treatment arms reduced tumour growth relative to control. The combination and RAS-inhibitor-only groups produced the greatest reductions, while pelareorep's individual contribution became less pronounced once dosing was shifted to a weekly schedule. Oncolytics is framing this as a dosing-optimisation question rather than a signal of limited utility, and said it will test additional schedules and RAS-driven tumour models in follow-on preclinical work.
Thomas Heineman, Chief Medical Officer of Oncolytics, said the findings offered "an encouraging first look at combining pelareorep with one of the most important emerging classes of targeted cancer therapies," and that biological compatibility between the two agents supported continued evaluation. He highlighted acquired resistance as the central clinical problem the combination might address, noting that pelareorep's selective tumour-cell infection mechanism appears unimpeded by RAS pathway blockade.
Scientific rationale
The company said the results are consistent with previously published independent research showing that RAS inhibitors do not block the mechanism by which pelareorep selectively infects tumour cells. That compatibility matters because a key concern with combining targeted agents and immunotherapies is mutual interference: if the targeted agent suppresses the immune environment that an oncolytic virus depends on, the combination collapses. The data, at least at this preclinical stage, suggest that concern may not apply here.
Pelareorep is an intravenously delivered, double-stranded RNA immunotherapeutic with a dual mechanism: it selectively replicates in tumour cells while stimulating both innate and adaptive anti-tumour immune responses. The agent has been administered to more than 1,200 patients across multiple solid-tumour studies. Oncolytics holds FDA Fast Track designation for pelareorep in colorectal, anal, and pancreatic cancer, which may help accelerate regulatory interactions as the combination programme matures.
Market context and competitive landscape
RAS inhibitors have reshaped the targetable-oncology landscape since the approval of KRAS G12C-specific agents. Pan-RAS inhibitors, which aim to cover a broader set of RAS mutations rather than a single point mutation, represent the next generation of this class and are currently in early-to-mid-stage clinical evaluation across several development-stage companies. Colorectal cancer is a particularly pressing indication: KRAS mutations are present in roughly 40 to 50 per cent of CRC cases, yet most patients with these mutations have historically had no targeted options.
Oncolytic virus platforms broadly face a translational challenge: impressive preclinical profiles have not always converted into registrational clinical results, and the field has seen notable late-stage setbacks in recent years. For Oncolytics, the combination strategy with RAS inhibitors offers a potential path to differentiating pelareorep in a crowded immuno-oncology space, particularly if durability-of-response data from optimised dosing schedules can be demonstrated. The company said it is actively pursuing strategic partnerships to accelerate development, and a well-characterised combination rationale could strengthen its position in those conversations.
Near-term milestones to watch include results from additional preclinical dosing schedules, any decision to file an IND for a pelareorep and RAS-inhibitor combination study, and updates on the ongoing gastrointestinal cancer clinical programme.